-22.9%
SPOT vs MRNA
+511.3%
-534.2%
-44.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.2% | -2.2% | -0.9% | -3.1% |
| 7D | -0.9% | +5.5% | -6.4% | -1.1% |
| 30D | +12.5% | +158.7% | -146.2% | +7.6% |
| 3M | +9.9% | +182.1% | -172.2% | +5.3% |
| 6M | +1.6% | +151.8% | -150.3% | -2.1% |
| YTD | -6.6% | +393.6% | -400.1% | -14.7% |
| 1Y | -22.9% | +499.5% | -522.4% | -30.6% |
| All | -22.9% | +511.3% | -534.2% | -30.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling